Nils-Petter Rudqvist

Sahlgrenska University Hospital — Sweden

Medicine · Health Sciences

24h-index3.6kcitations154works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(94), Immunotherapy and Immune Responses(49), CAR-T cell therapy research(37), Monoclonal and Polyclonal Antibodies Research(27), Immune Cell Function and Interaction(17)

Publications154 total

1344 AgenT-797, an allogeneic iNKT cell therapy, demonstrates durable clinical activity in solid tumors: updated phase 1 findings
2025Open Access
Supplementary Table S11 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S7 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S18 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S9 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S12 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S8 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Tables S1-S6 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S20 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S15 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S19 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S16 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S17 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S13 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S10 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Table S14 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Supplementary Figures S1-S18 from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
Data from Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
2025Open Access
CAR-iNKT cells: redefining the frontiers of cellular immunotherapy
Frontiers in Immunology·2025· 7 citedOpen Access
Early proteomic response in thyroid gland after 131I administration in female Balb/c mice
Radiation Protection Dosimetry·2025· 1 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Eva Forssell‐Aronsson(20), Khalil Helou(19), Britta Langen(17), Toshima Z. Parris(16), Sandra Demaria(13), Johan Spetz(13), Silvia C. Formenti(11), Erik Wennerberg(11), Emil Schüler(11), Claire Lhuillier(8), Lorenzo Galluzzi(7), Xi Kathy Zhou(6), Sheila Spada(6), Claire Vanpouille‐Box(4), Tuo Zhang(4), Karsten A. Pilones(4), Gennaro Ciliberto(4), Dhan Chand(4), Maud Charpentier(3), Michael A. Curran(3)